Tradipitant is under clinical development by Vanda Pharmaceuticals and currently in Pre-Registration for Gastroparesis. According to GlobalData, Pre-Registration drugs for Gastroparesis have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Tradipitant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tradipitant overview
Tradipitant (VLY-686, LY-686017) is under development for the treatment of gastroparesis, functional dyspepsia and motion sickness. It is administered through oral route as a capsule. The drug candidate is a new chemical entity that targets neurokinin-1 (NK-1) receptor. LY-686017 was also under development for the treatment of anxiety, social phobia, craving during anxiety associated alcohol dependence and treatment-resistant pruritus in atopic dermatitis.
It was under development for the treatment of pneumonia associated with Coronavirus disease 2019 (COVID-19).
Vanda Pharmaceuticals overview
Vanda Pharmaceuticals (Vanda) a biopharmaceutical company that develops and commercializes novel therapies for the treatment of central nervous system disorders. The company’s products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a typical antipsychotic for the treatment of schizophrenia in adults. The company’s major pipeline products include Tradipitant (VLY-686), VTR-297, VQW-765, CFTR and portfolio of cystic fibrosis transmembrane conductance regulator inhibitors and activators. Vanda is headquartered in Washington, Washington DC, the US.
For a complete picture of Tradipitant’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
